Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma—a phase 3 randomised trial

INTRODUCTION: There is a strong theoretical rationale for combining checkpoint blockade with cytotoxic chemotherapy in pleural mesothelioma and other cancers. Two recent single-arm, phase 2 trials [DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma (DREAM) and Phas...

Descripción completa

Detalles Bibliográficos
Autores principales: Kok, Peey Sei, Forde, Patrick M, Hughes, Brett, Sun, Zhuoxin, Brown, Chris, Ramalingam, Suresh, Cook, Alistair, Lesterhuis, Willem Joost, Yip, Sonia, O’Byrne, Ken, Pavlakis, Nick, Brahmer, Julie, Anagnostou, Valsamo, Ford, Kate, Fitzpatrick, Karen, Bricker, Alison, Cummins, Michelle M, Stockler, Martin, Nowak, Anna K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796233/
https://www.ncbi.nlm.nih.gov/pubmed/35078853
http://dx.doi.org/10.1136/bmjopen-2021-057663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796233/
https://www.ncbi.nlm.nih.gov/pubmed/35078853
http://dx.doi.org/10.1136/bmjopen-2021-057663

Ejemplares similares